Lab notes

How the MetaDose GLP-1 pricing model works

MetaDose is built as a cost lab, not a single coupon page. The Drug Matrix above pulls state-adjusted list prices for Ozempic (semaglutide, diabetes), Wegovy (semaglutide, weight management), Mounjaro (tirzepatide, diabetes), and Zepbound (tirzepatide, weight management). Those four brands share two molecules but different NDCs, indications, and formulary rules — which is why your insurer can approve one brand and reject another even when the active ingredient is the “same class.”

Our model starts from published manufacturer list prices, applies a state cost modifier that reflects regional pharmacy and benefit patterns, then layers the paths patients actually use: commercial copay with a manufacturer savings card, cash retail, NovoCare / Lilly-style assistance ranges, and compounded telehealth bands. We intentionally separate advertised monthly prices from steady-state monthly prices. An ad that says “$25/month” almost always assumes commercial insurance, an active prior authorization, and a savings card that has not hit its annual fill cap. Remove any of those conditions and the number jumps.

Use the Matrix to compare drugs side-by-side for one state, then open a state drug page (for example Ozempic in Texas or Wegovy in California) when you need local list figures and Medicare/Medicaid notes. Rankings across all fifty states live on the state affordability rankings tool.

Savings cards: what they are — and what they are not

Manufacturer savings cards (NovoCare for Ozempic/Wegovy, Lilly programs for Mounjaro/Zepbound) are the usual reason commercially insured patients see $25–$100 copays instead of $150–$400 specialty-tier coinsurance. They are not insurance. They do not work with Medicare, Medicaid, TRICARE, or VA coverage. They often limit the number of fills (commonly around twelve months of benefit) and cap the monthly savings amount. After the cap, you revert to your plan’s full copay or coinsurance — sometimes overnight, with no portal warning until the pharmacy runs the claim.

Before you enroll, read the current card terms and ask the pharmacy to reverse a test claim with the BIN/PCN on file. Our savings card guide covers eligibility pitfalls; Truth Checker™ lets you toggle a “card expired / capped” line so year-two cost is not a surprise. If you are uninsured, patient assistance programs are a different channel than copay cards — income documentation and a licensed prescriber submission are required, and timelines are weeks, not hours.

Prior authorization: the gate before any “$25” path

Most commercial plans require prior authorization for weight-loss GLP-1s, and many still PA diabetes brands on higher tiers. Approval packets typically need BMI (≥30, or ≥27 with a documented comorbidity such as hypertension, OSA, or dyslipidemia), recent labs when diabetes-indicated, proof of lifestyle or metformin step therapy, and a letter of medical necessity. Incomplete packets are the most common reason for first-pass denials — not “the drug is never covered.”

Budget for a 3–14 business day review window. If you are mid-titration, start the PA before your pen runs out so you do not bridge with expensive cash fills. When denied, read the reason code, request the plan’s clinical criteria, and escalate with peer-to-peer review plus comorbidities on the chart. See our prior authorization checklist and appeal guide for the paperwork sequence. The lab’s job is to estimate what you pay after that process succeeds — not to pretend denial rates are zero.

How to use the Affordability Audit™

The Affordability Audit™ is the full workflow when the Matrix alone is not enough. Pick your state, drug, coverage type (commercial, Medicare, Medicaid, cash, TRICARE/VA-style government), and whether a savings card applies. The audit returns a personal Affordability Score™, a monthly estimate, and a 12-month cumulative curve that accounts for titration months and card caps. That annual view matters: month one at $25 looks affordable; months 13–24 at specialty coinsurance may not.

Work the audit in this order: (1) confirm the indication matches the brand your plan actually covers — diabetes Ozempic/Mounjaro vs obesity Wegovy/Zepbound; (2) mark savings-card eligibility honestly; (3) add hidden line items the Truth Checker exposes — telehealth membership, labs, supply swabs/sharps, prior-auth bridge fills; (4) compare the score against a compounded or cash alternative only after you understand brand net cost with your real benefits. If you are shopping telehealth ads, open Truth Checker in a second tab and toggle every fee the landing page omits.

Nothing here is a prescription, medical advice, or a guarantee of coverage. Plan medical policies change mid-year; pharmacy quotes change by zip code. Use MetaDose to pressure-test the story an ad or benefits portal tells you, then verify the claim at your pharmacy and with your insurer before you commit to a long titration schedule.